{"id":"NCT02537431","sponsor":"Kyowa Kirin, Inc.","briefTitle":"Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)","officialTitle":"An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-23","primaryCompletion":"2017-08-30","completion":"2018-12-13","firstPosted":"2015-09-01","resultsPosted":"2018-09-25","lastUpdate":"2024-06-18"},"enrollment":14,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["X-linked Hypophosphatemia"],"interventions":[{"type":"BIOLOGICAL","name":"burosumab","otherNames":["KRN23","UX023","Crysvita"]}],"arms":[{"label":"Open-Label Burosumab Q4W","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).","primaryOutcome":{"measure":"Percent Change From Baseline in OV/BV at Week 48","timeFrame":"Baseline, 48 weeks","effectByArm":[{"arm":"Open-Label Burosumab Q4W","deltaMin":-54.18,"sd":20.211}],"pValues":[{"comp":"OG000","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States","Canada","Denmark","France","Japan","South Korea"]},"refs":{"pmids":["35775373"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":14},"commonTop":["Tooth Abscess","Procedural Pain","Back Pain","Pain","Arthralgia"]}}